Drugs / Umbilical cord blood mononuclear cells

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06792682 Feb 2025 → Dec 2027 expected Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 1 NCT01942915 Jan 2012 → Dec 2013 cirrhosis of liver Hebei Medical University Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT04689425 Mar 2021 → Dec 2023 ulcer of lower limbs Peking University Third Hospital Unknown No outcome recorded
Phase not applicable3 trials
NCT06729320 Dec 2024 → Jun 2025 overdue immune system disorder Beijing GoBroad Hospital Not yet recruiting No outcome recorded
NCT04882683 Jun 2021 → Jun 2022 ulcerative colitis Shandong Qilu Stem Cells Engineering Co., Ltd. Unknown No outcome recorded
NCT04997590 Dec 2020 → Dec 2021 Qianfoshan Hospital Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Umbilical Cord Blood Mononuclear Cells Umbilical cord blood mononuclear cells (MNC) may improve the wound repair ability.” NCT04689425
5

Umbilical Cord Blood Mononuclear CellsNCT06792682

NCT04882683

NCT01942915

NCT06729320

NCT04997590

Known as MNC “Umbilical cord blood mononuclear cells (MNC) may improve the wound repair ability.” NCT04689425
Modality Cell therapy “umbilical cord blood mononuclear cells transplantation” NCT01942915
Route Other “Participants will be transplanted with umbilical cord blood mononuclear cells.” NCT01942915